Biomea Fusion (BMEA) Expected to Announce Quarterly Earnings on Monday

Biomea Fusion (NASDAQ:BMEA) is anticipated to announce its quarterly earnings data before the market opens on Monday, April 7th. Analysts expect the company to announce earnings of ($1.00) per share for the quarter.

Biomea Fusion Trading Down 7.6 %

BMEA opened at $2.30 on Monday. The stock’s 50-day moving average price is $3.32 and its 200 day moving average price is $6.00. Biomea Fusion has a 12-month low of $2.27 and a 12-month high of $16.29. The firm has a market cap of $83.35 million, a price-to-earnings ratio of -0.57 and a beta of -0.26.

Analyst Ratings Changes

Several research firms have recently commented on BMEA. D. Boral Capital reissued a “buy” rating and issued a $16.00 price objective on shares of Biomea Fusion in a research note on Wednesday, March 19th. HC Wainwright reissued a “buy” rating and issued a $40.00 price target on shares of Biomea Fusion in a research report on Monday, March 24th. Finally, Oppenheimer set a $10.00 price objective on Biomea Fusion in a research report on Monday, March 24th. Two equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $24.64.

About Biomea Fusion

Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.